Page last updated: 2024-12-05

1,5-dihydroxynaphthalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,5-Dihydroxynaphthalene is a polycyclic aromatic hydrocarbon with two hydroxyl groups attached to the naphthalene ring at positions 1 and 5. It is a white to pale yellow solid that is soluble in organic solvents. This compound is a key intermediate in the synthesis of various dyes, pharmaceuticals, and other organic compounds. The synthesis of 1,5-dihydroxynaphthalene can be achieved through various methods, including the oxidation of naphthalene, the sulfonation of 1-naphthol, and the Friedel-Crafts acylation of benzene with 1,5-dichloronaphthalene. 1,5-dihydroxynaphthalene has been investigated for its potential biological activity, exhibiting antioxidant and anti-inflammatory properties. Research on this compound focuses on its applications in materials science, as it can be used to synthesize polymers, composites, and other functional materials. Its unique structural properties, coupled with its potential applications in different fields, make 1,5-dihydroxynaphthalene a subject of continued research interest.'

Cross-References

ID SourceID
PubMed CID6749
CHEMBL ID204658
SCHEMBL ID28327
MeSH IDM0091190

Synonyms (57)

Synonym
BIDD:GT0202
STL290515
nsc7202
oxidation base
1,5-dihydroxynapthalene
nsc-7202
durafur developer e
83-56-7
c.i. 76625
ci 76625
1,5-dihydroxynaphthalene ,
1,5-naphthalenediol
brn 2044951
einecs 201-487-4
ai3-16636
nsc 7202
inchi=1/c10h8o2/c11-9-5-1-3-7-8(9)4-2-6-10(7)12/h1-6,11-12
naphthalene-1,5-diol
1,5-dihydroxynaphthalene, 97%
AC-11727
D0590
CHEMBL204658
naphthalene-1,5-diol;1,5-dihydroxynaphthalene
A19217
AKOS005287408
1,5-dihydroxy naphthalene
p25hc23vh6 ,
unii-p25hc23vh6
4-06-00-06554 (beilstein handbook reference)
ec 201-487-4
FT-0606961
1,5-dihydroxynaphthaline
1,5-naphthohydroquinone
1,5-naphthalenediol [inci]
bdbm36287
SCHEMBL28327
1.5-naphthalenediol
1,5-dihydroxynaphtalene
1,5-dihydroxy-naphthalene
NCGC00357051-01
dtxcid9031147
tox21_303746
cas-83-56-7
dtxsid2052574 ,
W-104138
Z276600344
1,5-dihydroxy naphthalene;
mfcd00003980
F0001-2128
CS-0015800
1,5-naphthalindiol
AS-12844
1-hydroxy-5-naphthol
Q19842073
EN300-52581
D72512
1,5-dihydroxynaphthaline; 1,5-naphthohydroquinone; c.i. 76625; durafur developer e; nsc 7202; oxidation base
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency63.26090.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency64.86010.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency12.82390.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency61.13060.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency26.16390.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.42680.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency48.55770.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.01130.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.72640.000229.305416,493.5996AID1259244; AID1259248
thyroid stimulating hormone receptorHomo sapiens (human)Potency76.95880.001628.015177.1139AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency6.54060.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency63.54700.039147.5451146.8240AID1224845
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.48270.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.48270.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID261690Antiproliferative activity against human fibroblast HFL1 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID261691Antiproliferative activity against human bladder carcinoma T24 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's5 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.62 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index37.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]